No Data
No Data
Orchestra BioMed Hldgs Is Maintained at Buy by Chardan Capital
Orchestra BioMed Hldgs Is Maintained at Buy by Chardan Capital
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.
Piper Sandler Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Orchestra BioMed Hldgs (NASDAQ:OBIO) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.38) by 2.63 percent. This is a 428.57 percent decrease over losses
Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data
Orchestra BioMed Holdings 2023 Rev $2.8M >OBIO
Orchestra BioMed Holdings 2023 Rev $2.8M >OBIO
No Data